FILE:LH/LH-8K-20070724075418.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company dated July 24, 2007.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
8-K Filed July 24, 2007
1
 
            
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.  Actual results could differ materially from those suggested by these forward- looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2006, and subsequent SEC filings.
2
 
The Clinical Laboratory Testing Market > $40 - $50 billion Annually
Industry CAGR of 5% - 7%
Market segments:
Routine ~ $30 - $35 billion
Esoteric ~ $4 - $5 billion
Anatomic pathology ~ $6 - $10 billion
Growth opportunities:
Consolidation
Esoteric and anatomic pathology testing
Hospital outpatient and outreach
Source:    Company estimates, industry reports and 2006 revenue for LabCorp.
3
 
Industry Profile
Integral to quality healthcare
Screening for and early diagnosis of disease leads to improved outcomes
Monitoring of treatment effectiveness and disease recurrence
Correct therapy decisions based on known genetic markers
Cost effectiveness
Cutting-edge technologies
Influences 70% - 80% of healthcare decisions
Rigorous quality standards
4
 
Profile of LabCorp
The leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
Offers the broadest range of clinical and anatomic pathology services to aid clinicians in diagnosis, monitoring, prediction and prevention of disease
Conducts > 300 million tests annually
Connectivity with physicians offices
90% of results delivered electronically
70% of tests ordered electronically
5
 
Profile of LabCorp
More than 25,000 employees nationwide
6,200 phlebotomists
2,600 couriers
700 MDs and PhDs
1,700 conveniently located patient service centers
Rigorously monitored, industry-leading quality and service metrics
Highest quality, CAP inspected and CLIA certified laboratories
6
 
Primary Testing Locations
Primary LabCorp Testing Locations
Corporate Headquarters
Burlington, NC
7
 
What is LabCorp?
Clinical Pathology
Medical
Testing
Services
Esoteric
Testing
Genomics
Anatomic Pathology
8
 
Strategic Focus Areas
Scientific
Leadership
Managed
Care
Customer
Focus
Cancer diagnostics and monitoring
Advanced cardiovascular disease testing
Quality and service driven culture
Continuous enhancements in customer connectivity
First-time problem resolution
Advancement through acquisitions and licensing
Partner to control high cost leakage
Lab data enables better treatment and outcomes
Recognize
v
alue of lab services through appropriate pricing
9
 
Revenue Growth Drivers
Managed Care
Partner of choice for major managed care organizations
Recognition of value from standardized lab data
Breadth of test menu, quality, convenience
Cancer diagnostics
Anatomic pathology - $6 - $10 billion fragmented market
Treatment decisions/monitoring
Recurrence testing
Cardiovascular disease
Lab testing is foundation for determining need for imaging, invasive procedures, pharmaceutical treatments
VAP, NMR, high-sensitivity CRP
10
 
EBITDA Margin Growth Drivers
Increased volumes through fixed-cost infrastructure
Larger number of esoteric tests offered, more esoteric tests ordered
Further operational efficiencies
Increase automation in pre-analytic processes
Logistics / route structure optimization
Supply chain management
Improvement in collections / bad debt
11
 
LabCorp's Investment and Performance Fundamentals
Industry-leading EBITDA margins
Significant free cash flow
Focus on returning value to shareholders
Strategic acquisitions
Organic growth opportunities
Share repurchase  additional $500 million authorization announced 3/13/07
Flexibility for future growth opportunities
12
 
Five-Year Revenue and EPS Trend
Revenue CAGR of 9%   -   Diluted EPS CAGR of 19%
(1)
(1)
Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non- recurring investment loss.
(2)
Excluding the $0.07 per diluted share impact in 2006 of restructuring and other special charges, and the $0.10 per diluted share impact in 2006 of adoption of SFAS 123(R).
13
 
Five-Year OCF and EBITDA Margin Trend
OCF CAGR of 9%   -   EBITDA Margin Growth of 420 bps
(1)
Includes approximately $50 million of benefit from one-time tax credits recorded in 2003.
(2)
Excluding the impact in 2005 of restructuring and other special charges and a non-recurring investment loss.
(3)
Excluding the impact in 2006 of restructuring and other special charges and of the adoption of SFAS 123(R).
14
 
Second Quarter Results
(in millions, except per share data)
6/30/2006
6/30/2007
+/(-)
Revenue
903.7
$     
1,043.1
$  
15.4%
EBITDA
(1)
247.1
$     
279.6
$     
13.1%
EBITDA Margin
27.3%
26.8%
(50)
   
bp
Diluted EPS
(2)
0.87
$        
1.09
$        
25.3%
(1)  Excludes restructuring and other special charges of $7.0 million recorded by the
Company in the second quarter of 2007.
(2)  Excludes the $0.04 per diluted share impact of the restructuring and other special
charges recorded in the second quarter of 2007.
15
 
Six-Month Results
(in millions, except per share data)
6/30/2006
6/30/2007
+/(-)
Revenue
1,782.2
$  
2,041.8
$  
14.6%
EBITDA
(1)
470.9
$     
540.1
$     
14.7%
EBITDA Margin
26.4%
26.5%
10
     
bp
Diluted EPS
(2)
1.62
$        
2.06
$        
27.2%
(1)  Excludes restructuring and other special charges of $7.0 million recorded by the
Company in the second quarter of 2007.
(2)  Excludes the $0.03 per diluted share impact of the restructuring and other special
charges recorded in the second quarter of 2007.
16
 
2007 Second Quarter Financial Achievements
Diluted EPS of $1.09
(1)
EBITDA margin of 26.8% of net sales
(2)
Operating cash flow of $153.1 million
Increased revenues 15.4% (14.2% volume; 1.2% price)
Repurchased approximately $51.5 million of LabCorp stock
(1)  Excludes the $0.04 per diluted share impact of the restructuring and other special charges recorded in the second quarter of 2007.
(2)  Based on EBITDA of $279.6 million, excluding the $7.0 million impact of restructuring and other special charges.
17
 
2007 First Half Financial Achievements
Diluted EPS of $2.06
(1)
EBITDA margin of 26.5% of net sales
(2)
Operating cash flow of $338.9 million
Increased revenues 14.6% (13.3% volume; 1.3% price)
Repurchased approximately $409.5 million of LabCorp stock
(1)  Excludes the $0.03 per diluted share impact of the restructuring and other special charges recorded in the second quarter of 2007.
(2)  Based on EBITDA of $540.1 million, excluding the $7.0 million impact of restructuring and other special charges.
18
 
Revenue by Payer  Q2-YTD-2007
(in millions)
Managed Care 
Fee-for-service
$860.7
42%
Client
$525.1
26%
Patient
$195.5
10%
Medicare & Medicaid
$373.7
18%
Managed Care 
Capitated
$86.8
4%
19
 
Revenue by Business Area  Q2 YTD-2007
(in millions)
Core
$1,343.1
66%
Genomic
$314.3
15%
Other Esoteric
$220.3
11%
Histology
$164.1
8%
20
 
Revenue Mix by Business Area
(in millions)
21
 
Revenue by Payer
(in millions, except PPA)
YTD Q2-2005
YTD Q2-2006
YTD Q2-2007
Revenue
Revenue
Revenue
$'s
%
Accns
PPA
$'s
%
Accns
PPA
$'s
%
Accns
PPA
Client
465.1
$   
28%
15.939
29.18
$  
487.0
$   
27%
16.645
29.26
$  
525.1
$   
26%
17.071
30.76
$  
Patient
152.9
   
9%
1.178
  
129.80
$
169.7
     
10%
1.148
  
147.81
$
195.5
   
10%
1.226
  
159.44
$
Third Party
(Medicare/Medicaid)
373.2
   
23%
9.825
  
37.98
$  
379.5
     
21%
9.405
  
40.35
$  
373.7
   
18%
9.221
  
40.53
$  
Managed Care:
- Capitated
68.6
      
4%
6.653
  
10.31
$  
70.7
      
4%
6.701
  
10.55
$  
86.8
      
4%
7.765
  
11.18
$  
- Fee for service
592.6
   
36%
12.624
46.94
$  
675.3
     
38%
13.768
49.05
$  
860.7
   
42%
18.662
46.12
$  
  Total Managed Care
661.2
   
40%
19.277
34.30
$  
746.0
     
42%
20.469
36.44
$  
947.5
   
46%
26.427
35.85
$  
LabCorp Total
1,652.4
$
100%
46.219
35.75
$  
1,782.2
$
100%
47.667
37.39
$  
2,041.8
$
100%
53.945
37.85
$  
22
 
Revenue Mix by Business Area
(in millions, except PPA)
YTD Q2-2005
YTD Q2-2006
YTD Q2-2007
Revenue
Revenue
Revenue
$'s
%
Accns
PPA
$'s
%
Accns
PPA
$'s
%
Accns
PPA
All Genomic
252.1
$   
15%
3.350
  
75.23
$  
274.4
$   
15%
3.543
  
77.45
$  
314.3
$   
15%
4.246
  
74.01
$  
Other Esoteric
159.4
     
10%
3.892
  
40.97
   
190.8
   
11%
4.577
  
41.69
   
220.3
   
11%
5.396
  
40.83
   
Histology
134.5
     
8%
1.195
  
112.53
  
147.9
   
8%
1.195
  
123.79
  
164.1
   
8%
1.367
  
120.02
  
  All Genomic / Esoteric
546.0
     
33%
8.437
  
64.71
   
613.1
   
34%
9.315
  
65.83
   
698.7
   
34%
11.009
63.47
   
Core
1,106.4
   
67%
37.782
29.28
   
1,169.1
  
66%
38.352
30.48
   
1,343.1
  
66%
42.936
31.28
   
  LabCorp Total
1,652.4
$
100%
46.219
35.75
$  
1,782.2
$
100%
47.667
37.39
$  
2,041.8
$
100%
53.945
37.85
$  
23
 
2007 Financial Guidance
Excluding the impact of any share repurchase activity after June 30, 2007,
and excluding restructuring and other special charges recorded in 2007,
guidance for 2007 is as follows:
Net sales growth of approximately 13% to 14% compared to 2006
EBITDA margins of 26.4% to 26.9% of net sales
Diluted EPS in the range of $4.11 to $4.27
Operating cash flow of between $690 and $710 million, excluding any transition payments related to the Company's agreement with UnitedHealthcare
Capital expenditures of between $100 and $110 million, excluding any additional capital expenditures related to the Company's agreement with UnitedHealthcare
Net interest expense of approximately $45 million
Bad debt rate of approximately 4.8% of net sales
24
 
Supplemental Financial Information
YTD
Q1 07
Q2 07
2007
Depreciation
26.3
$         
26.1
$         
52.4
$         
Amortization
13.3
$         
13.4
$         
26.7
$         
Capital expenditures
40.8
$         
32.2
$         
73.0
$         
Cash flows from operations
185.8
$      
153.1
$        
338.9
$      
Bad debt as a percentage of sales
4.83%
4.83%
4.83%
Effective interest rate on debt:
  Zero coupon-subordinated notes
2.00%
2.00%
2.00%
  5 1/2% Senior Notes (including effect of interest rate swap)
5.38%
5.38%
5.38%
  5 5/8% Senior Notes
5.75%
5.75%
5.75%
  Revolving credit facility (weighted average)
5.80%
5.80%
5.80%
Days sales outstanding
55
              
55
               
55
              
Laboratory Corporation of America
Other Financial Information
June 30, 2007
($ in million's)
25
 
Reconciliation of Non-GAAP Financial Measures
($ in millions)
26
 


